| 1 |
tissue plasminogen activator
(8409 times)
|
Vascular Diseases
(1950 times)
|
PAI-1 (1518 times)
uPA (623 times)
PAI (346 times)
|
1978 Inhibition of plasminogen activator production in organ cultures by cycloheximide.
|
| 2 |
tissue-type PA
(169 times)
|
Biochemistry
(20 times)
|
uPA (102 times)
PA (93 times)
PAs (49 times)
|
1985 Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages.
|
| 3 |
tissue PA
(25 times)
|
Neoplasms
(4 times)
|
uPA (15 times)
PA (13 times)
PAs (8 times)
|
1984 Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas.
|
| 4 |
trans-parinaric acid
(14 times)
|
Colloids
(6 times)
|
DPH (6 times)
POPC (5 times)
DPPC (3 times)
|
1986 Endotoxin protects against hyperoxic decrease in membrane fluidity in endothelial cells but not in fibroblasts.
|
| 5 |
tissue plasminogen
(9 times)
|
Vascular Diseases
(3 times)
|
HDL-C (3 times)
PAI-1 (3 times)
TC (2 times)
|
1992 The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review.
|
| 6 |
tissue Plg activator
(8 times)
|
Biochemistry
(3 times)
|
Pg (3 times)
PLG (3 times)
uPA (3 times)
|
1992 Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation.
|
| 7 |
therapy
(6 times)
|
Medicine
(2 times)
|
PTCA (2 times)
AMI (1 time)
CABG (1 time)
|
1990 Implications of the TIMI Trials.
|
| 8 |
trans-palmitoleic acid
(4 times)
|
Medicine
(1 time)
|
TVA (3 times)
EA (2 times)
cPA (1 time)
|
2017 Trans Fatty Acids Suppress TNF-alpha-Induced Inflammatory Gene Expression in Endothelial (HUVEC) and Hepatocellular Carcinoma (HepG2) Cells.
|
| 9 |
parameters-tissue plasminogen activator
(2 times)
|
Transplantation
(1 time)
|
CAD (1 time)
hsCRP (1 time)
ICAM (1 time)
|
2008 Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients.
|
| 10 |
tissue plasminogen activator signal peptide
(2 times)
|
Medicine
(1 time)
|
ECF (1 time)
ITM (1 time)
|
2011 DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
|
| 11 |
tissue recombinant plasminogen activator
(2 times)
|
Neurology
(2 times)
|
---
|
2007 Sonothrombolysis: experimental evidence.
|
| 12 |
treated with intravenous alteplase
(2 times)
|
Neurology
(2 times)
|
BAO (1 time)
NSPP (1 time)
sICH (1 time)
|
2011 Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.
|
| 13 |
TTPeak
(2 times)
|
Vascular Diseases
(1 time)
|
rFVIIa (1 time)
|
2011 Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
|
| 14 |
types of plasminogen activator, tissue-type
(2 times)
|
Endocrinology
(1 time)
|
uPA (2 times)
PAI-1 (1 time)
|
1993 The plasminogen activator and inhibitor system in bone remodelling.
|
| 15 |
components, plasminogen activator
(1 time)
|
General Surgery
(1 time)
|
CM (1 time)
EC (1 time)
HUV (1 time)
|
1993 Ambient oxygen tension modulates endothelial fibrinolysis.
|
| 16 |
dofetilide, patient-controlled analgesia pump, and alteplase
(1 time)
|
|
GSE (1 time)
PACE (1 time)
PSE (1 time)
|
2019 Evaluation of a Hospital Pharmacist Annual Competency Program.
|
| 17 |
long-term functional outcome for patients who receive intravenous alteplase
(1 time)
|
Health Services
(1 time)
|
DTN (1 time)
mRS (1 time)
MUSC (1 time)
|
2018 Long-Term Functional Outcome of Telestroke Patients Treated Under Drip-and-Stay Paradigm Compared with Patients Treated in a Comprehensive Stroke Center: A Single Center Experience.
|
| 18 |
tert-pentyl acrylamide
(1 time)
|
Chemistry Techniques, Analytical
(1 time)
|
LB (1 time)
|
2008 Molecular orientation of azobenzene chromophores in ultrathin polymer nanosheets studied by attenuated total reflection spectroscopy.
|
| 19 |
therapeutic
(1 time)
|
Biology
(1 time)
|
MCA (1 time)
|
2011 Modeling stroke in mice - middle cerebral artery occlusion with the filament model.
|
| 20 |
therapy was unavailability of alteplase
(1 time)
|
Vascular Diseases
(1 time)
|
---
|
2017 Egyptian experience in increasing utilization of reperfusion therapies in acute ischemic stroke.
|
| 21 |
therapy with alteplase
(1 time)
|
Vascular Diseases
(1 time)
|
---
|
2015 Endovascular thrombolysis to salvage central venous access in children with catheter-associated upper extremity deep vein thrombosis: technique and initial results.
|
| 22 |
thrombin inhibition by PAI-1 2.5-fold and of thrombin-VR1
(1 time)
|
Molecular Biology
(1 time)
|
PAI-1 (1 time)
|
1999 The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
|
| 23 |
thrombolysis with alteplase
(1 time)
|
Neurology
(1 time)
|
DWI (1 time)
FLAIR (1 time)
MRI (1 time)
|
2012 [EU-funded treatment study: WAKE-UP: a randomized, placebo-controlled MRI-based trial of thrombolysis in wake-up stroke].
|
| 24 |
thrombolytic activity of alteplase
(1 time)
|
Vascular Diseases
(1 time)
|
---
|
2022 Impact of poly-arginine peptides R18D and R18 on alteplase and tenecteplase thrombolysis in vitro, and neuroprotective stability to proteolysis.
|
| 25 |
Tissue plasminogen inhibitor
(1 time)
|
Hematology
(1 time)
|
CRP (1 time)
ERalpha (1 time)
ERbeta (1 time)
|
2010 Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens.
|
| 26 |
total PA, and tissue PA
(1 time)
|
Reproductive Medicine
(1 time)
|
PA (1 time)
uPA (1 time)
|
2004 [How chronic prostatitis affects plasminogen activator system].
|
| 27 |
transfected with pSVtPA
(1 time)
|
Vascular Diseases
(1 time)
|
UK (1 time)
|
1993 High-level expression of antibody-plasminogen activator fusion proteins in hybridoma cells.
|
| 28 |
transfected with these constructs, pSVtPA
(1 time)
|
Vascular Diseases
(1 time)
|
UK (1 time)
|
1993 High-level expression of antibody-plasminogen activator fusion proteins in hybridoma cells.
|
| 29 |
treatment and cost of administration of alteplase
(1 time)
|
Vascular Diseases
(1 time)
|
MI (1 time)
r-PA (1 time)
|
2000 Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA.
|
| 30 |
treatment for ischemic stroke is intravenous administration of plasminogen activator
(1 time)
|
Medicine
(1 time)
|
---
|
2013 Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation.
|
| 31 |
trials of alteplase
(1 time)
|
Medicine
(1 time)
|
---
|
2016 Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis.
|
A Search Service for Abbreviation / Long Form